NanoViricides, Inc. (NNVC.PK) Submits DengueCide Orphan Drug Designation Letter of Intent to File With the European Medicines Agency
7/1/2013 8:34:29 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC) (the "Company") announced today that it has submitted its letter of intent to file an Orphan Drug Application with the European Medicines Agency (EMA) for DengueCide™, its drug candidate for the treatment of dengue and dengue hemorrhagic fever. EMA requires a notification of intent to file at least 60 days prior to the actual filing, unlike the US FDA. The actual application will need to be translated into 27 different languages prior to submission.
Help employers find you! Check out all the jobs and post your resume.